SK bioscience Statistics
Total Valuation
SK bioscience has a market cap or net worth of KRW 3.53 trillion. The enterprise value is 2.99 trillion.
Market Cap | 3.53T |
Enterprise Value | 2.99T |
Important Dates
The next estimated earnings date is Tuesday, August 12, 2025.
Earnings Date | Aug 12, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
SK bioscience has 78.37 million shares outstanding. The number of shares has increased by 0.72% in one year.
Current Share Class | 78.37M |
Shares Outstanding | 78.37M |
Shares Change (YoY) | +0.72% |
Shares Change (QoQ) | +0.26% |
Owned by Insiders (%) | 0.11% |
Owned by Institutions (%) | 3.57% |
Float | 25.88M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 8.84 |
PB Ratio | 1.73 |
P/TBV Ratio | 2.09 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | -62.69 |
EV / Sales | 7.47 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | -18.04 |
Financial Position
The company has a current ratio of 4.46, with a Debt / Equity ratio of 0.20.
Current Ratio | 4.46 |
Quick Ratio | 3.78 |
Debt / Equity | 0.20 |
Debt / EBITDA | n/a |
Debt / FCF | -2.44 |
Interest Coverage | -21.48 |
Financial Efficiency
Return on equity (ROE) is -2.17% and return on invested capital (ROIC) is -3.70%.
Return on Equity (ROE) | -2.17% |
Return on Assets (ROA) | -3.25% |
Return on Invested Capital (ROIC) | -3.70% |
Return on Capital Employed (ROCE) | -4.91% |
Revenue Per Employee | 406.33M |
Profits Per Employee | -48.40M |
Employee Count | 984 |
Asset Turnover | 0.17 |
Inventory Turnover | 2.19 |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -21.81% in the last 52 weeks. The beta is 1.18, so SK bioscience's price volatility has been higher than the market average.
Beta (5Y) | 1.18 |
52-Week Price Change | -21.81% |
50-Day Moving Average | 40,403.00 |
200-Day Moving Average | 48,546.00 |
Relative Strength Index (RSI) | 68.12 |
Average Volume (20 Days) | 158,040 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, SK bioscience had revenue of KRW 399.83 billion and -47.63 billion in losses. Loss per share was -613.92.
Revenue | 399.83B |
Gross Profit | 50.75B |
Operating Income | -125.46B |
Pretax Income | -83.10B |
Net Income | -47.63B |
EBITDA | -64.19B |
EBIT | -125.46B |
Loss Per Share | -613.92 |
Balance Sheet
The company has 1.18 trillion in cash and 403.18 billion in debt, giving a net cash position of 780.38 billion or 9,957.77 per share.
Cash & Cash Equivalents | 1.18T |
Total Debt | 403.18B |
Net Cash | 780.38B |
Net Cash Per Share | 9,957.77 |
Equity (Book Value) | 2.04T |
Book Value Per Share | 23,081.62 |
Working Capital | 1.20T |
Cash Flow
In the last 12 months, operating cash flow was -33.71 billion and capital expenditures -131.84 billion, giving a free cash flow of -165.55 billion.
Operating Cash Flow | -33.71B |
Capital Expenditures | -131.84B |
Free Cash Flow | -165.55B |
FCF Per Share | -2,112.40 |
Margins
Gross margin is 12.69%, with operating and profit margins of -31.38% and -11.91%.
Gross Margin | 12.69% |
Operating Margin | -31.38% |
Pretax Margin | -20.78% |
Profit Margin | -11.91% |
EBITDA Margin | -16.05% |
EBIT Margin | -31.38% |
FCF Margin | n/a |
Dividends & Yields
SK bioscience does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -0.72% |
Shareholder Yield | n/a |
Earnings Yield | -1.35% |
FCF Yield | -4.68% |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
SK bioscience has an Altman Z-Score of 3.55.
Altman Z-Score | 3.55 |
Piotroski F-Score | n/a |